These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 3890756)

  • 1. [Endocrine therapy of recurrent breast cancer].
    Nomura Y; Tashiro H
    Gan To Kagaku Ryoho; 1985 Mar; 12(3 Pt 1):421-7. PubMed ID: 3890756
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Present status of endocrine therapy of breast cancer: a surgeon's view].
    Nomura Y
    Gan To Kagaku Ryoho; 1984 May; 11(5):981-8. PubMed ID: 6426405
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Steroid receptors in breast cancer.
    Desombre ER
    Monogr Pathol; 1984; (25):149-74. PubMed ID: 6377047
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Changing receptor status and treatment in breast cancer].
    Nomura Y
    Gan No Rinsho; 1983 May; 29(6):644-7. PubMed ID: 6876434
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chemoendocrine compared with endocrine adjuvant therapies for node-negative breast cancer: predictive value of centrally reviewed expression of estrogen and progesterone receptors--International Breast Cancer Study Group.
    Viale G; Regan MM; Maiorano E; Mastropasqua MG; Golouh R; Perin T; Brown RW; Kovács A; Pillay K; Ohlschlegel C; Braye S; Grigolato P; Rusca T; Gelber RD; Castiglione-Gertsch M; Price KN; Goldhirsch A; Gusterson BA; Coates AS
    J Clin Oncol; 2008 Mar; 26(9):1404-10. PubMed ID: 18349391
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Therapy for recurrent breast cancer].
    Terasawa T; Koyama H; Wada T; Nishizawa I; Shiba E; Kajita A
    Gan To Kagaku Ryoho; 1985 Mar; 12(3 Pt 1):428-38. PubMed ID: 3890757
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Content of epidermal growth factor receptor in metastatic breast cancer: its role in endocrine sensitivity prediction.
    Nesković-Konstantinović ZB; Nikolić-Vukosavljević DB; Branković-Magić MV; Mitrovic LB; Spuzić I
    Neoplasma; 2000; 47(2):107-13. PubMed ID: 10985476
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Adjuvant endocrine forms of therapy in breast cancer].
    Jakesz R; Hausmaninger H
    Wien Klin Wochenschr; 1984 Jun; 96(13):492-9. PubMed ID: 6475078
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Primary endocrine therapy in locally advanced breast cancers--the Nottingham experience.
    Mathew J; Agrawal A; Asgeirsson KS; Buhari SA; Jackson LR; Cheung KL; Robertson JF
    Breast Cancer Res Treat; 2009 Jan; 113(2):403-7. PubMed ID: 18311583
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Influence of estrogen receptor status on response to combination chemotherapy for recurrent breast cancer.
    Mortimer J; Reimer R; Greenstreet R; Groppe C; Bukowski R
    Cancer Treat Rep; 1981; 65(9-10):763-6. PubMed ID: 7273011
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Place of hormone receptor determination in the therapeutic strategy of breast cancer].
    Clavel B; Gest J
    Pathol Biol (Paris); 1983 Dec; 31(10):809-18. PubMed ID: 6366702
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Endocrine management of breast cancer.
    Schneider PG; Jackisch C; Brandt B
    Int J Fertil Menopausal Stud; 1994; 39 Suppl 2():115-27. PubMed ID: 7874188
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Chemo-endocrine therapy of advanced breast cancer].
    Nomura Y
    Gan To Kagaku Ryoho; 1988 Dec; 15(12):3214-20. PubMed ID: 2973769
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dissemination of adjuvant multiagent chemotherapy and tamoxifen for breast cancer in the United States using estrogen receptor information: 1975-1999.
    Mariotto AB; Feuer EJ; Harlan LC; Abrams J
    J Natl Cancer Inst Monogr; 2006; (36):7-15. PubMed ID: 17032888
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expression of prostate-specific antigen (PSA) correlates with poor response to tamoxifen therapy in recurrent breast cancer.
    Foekens JA; Diamandis EP; Yu H; Look MP; Meijer-van Gelder ME; van Putten WL; Klijn JG
    Br J Cancer; 1999 Feb; 79(5-6):888-94. PubMed ID: 10070886
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Selection of therapeutic procedures according to the clinicopathological features of breast cancer].
    Izuo M; Yokoe T
    Gan To Kagaku Ryoho; 1986 Jan; 13(1):37-45. PubMed ID: 2935084
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics.
    Ellis MJ; Tao Y; Luo J; A'Hern R; Evans DB; Bhatnagar AS; Chaudri Ross HA; von Kameke A; Miller WR; Smith I; Eiermann W; Dowsett M
    J Natl Cancer Inst; 2008 Oct; 100(19):1380-8. PubMed ID: 18812550
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Re-evaluating adjuvant breast cancer trials: assessing hormone receptor status by immunohistochemical versus extraction assays.
    Regan MM; Viale G; Mastropasqua MG; Maiorano E; Golouh R; Carbone A; Brown B; Suurküla M; Langman G; Mazzucchelli L; Braye S; Grigolato P; Gelber RD; Castiglione-Gertsch M; Price KN; Coates AS; Goldhirsch A; Gusterson B;
    J Natl Cancer Inst; 2006 Nov; 98(21):1571-81. PubMed ID: 17077359
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Internal endocrine therapy of breast cancer].
    Yoshida M; Miura S
    Gan To Kagaku Ryoho; 1984 May; 11(5):989-98. PubMed ID: 6372698
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term pattern of disease recurrence among patients with early-stage breast cancer according to estrogen receptor status and use of adjuvant tamoxifen.
    Khoshnoud MR; Fornander T; Johansson H; Rutqvist LE
    Breast Cancer Res Treat; 2008 Jan; 107(1):71-8. PubMed ID: 18043896
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.